Related Experiment Video
Updated: May 10, 2026
Large Scale Zebrafish-Based In vivo Small Molecule Screen
Published on: December 30, 2010
In vivo effects of antiviral protein kinase C modulators on zebrafish development and survival
Richard V Davis1, Lisa N McKernan, Jennifer Rhodes
1Department of Biology, Chestnut Hill College, Philadelphia, PA 19118, USA.
Abstract:
Clinical interventions using protein kinase C (PKC) modulators have been proposed for eradication of HIV-1-infected cellular reservoirs which persist in patients despite prolonged antiretroviral therapy. The effects of some of these agents have not been assessed in a developing vertebrate model. This study examines the developmental and toxicological effects of these compounds on zebrafish embryos and larvae. Treatment of zebrafish through the first week of development with various PKC pathway modulators did not elicit gross physical defects or elevated incidences of death at lower doses. Higher concentrations resulted in rapid death for both later-stage embryos and larvae. Each compound had a threshold dose for lethality. The defined nonlethal doses may be useful toward assessing the effects of modulating PKC activity on zebrafish development. They may further provide some guidance for the potential dosing of PKC modulators in clinical trials toward the goal of HIV-1 reservoir eradication.
Insights
Protein kinase C (PKC) modulators show promise for HIV-1 reservoir eradication. Zebrafish studies reveal nonlethal doses for development, guiding future clinical trial dosing.
Area of Science:
- Developmental toxicology
- Pharmacology
- Virology
Background:
- Protein kinase C (PKC) modulators are investigated for eradicating persistent HIV-1 reservoirs.
- Assessing these agents in vertebrate models is crucial for clinical translation.
- Zebrafish offer a suitable model for developmental and toxicological studies.
Purpose of the Study:
- To evaluate the developmental and toxicological effects of PKC pathway modulators in zebrafish embryos and larvae.
- To determine safe, nonlethal doses for potential therapeutic applications.
- To inform clinical trial dosing strategies for HIV-1 reservoir eradication.
Main Methods:
- Zebrafish embryos and larvae were exposed to various PKC pathway modulators during the first week of development.
- Developmental and toxicological endpoints, including gross physical defects and mortality, were assessed.
- Dose-response relationships and lethal threshold doses were determined for each compound.
Main Results:
- Low doses of PKC modulators did not cause significant developmental defects or mortality in zebrafish.
- Higher concentrations led to rapid death in later-stage embryos and larvae.
- Each compound exhibited a specific threshold dose for lethality.
Conclusions:
- Defined nonlethal doses of PKC modulators in zebrafish can be used to study developmental effects.
- These findings provide guidance for potential clinical trial dosing of PKC modulators for HIV-1 reservoir eradication.
- Zebrafish serve as a valuable vertebrate model for assessing the safety of potential HIV therapies.
